TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07538570: A Phase 4, Double-blind, Sequential Cohort Study of Pain Treatment and Recovery After Total Knee Arthroplasty

Sponsor: Vertex Pharmaceuticals Incorporated · Phase: PHASE4 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 60 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$7,463,360

Rescue Site Savings

+$4,913,600

Unlock Full NCT07538570 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07538570 Rescue Dossier →